A small desk with a strict standard.

Aminoscope is owned and published by MEAS Partners, LLC, a Delaware limited liability company. The writing is done by a desk of four writers, each with a defined beat, who publish under disclosed pen names (more on that below). The site covers 373 evidence articles, 473 telehealth provider reviews, and a set of free tools such as the evidence matrix and the GLP-1 cost estimator.

Aminoscope is not a medical provider, a pharmacy or a telehealth company, and nothing here is medical advice. See the medical disclaimer.

Aminoscope earns affiliate commissions. When a reader follows one of our partner links and starts care with that provider, we may be paid a commission, at no extra cost to the reader. Partner links are managed mainly through the Katalys affiliate network, plus a few direct partnerships with telehealth providers and pharmacies.

Here is what that does and does not change. On the provider roundups under /best, partners are listed first and carry a small “Partner” tag. That order is commercial, not a judgment that a partner is better. What a commission never changes is what we write: a partner is held to the same evidence bar as a provider we earn nothing from, its warning letters and weak points are reported the same way, and we cover many providers we have no relationship with, linking to them directly. The full terms are in our disclosures and how we review providers.

• Primary sources only. Every figure in an evidence article is tied to the trial publication, the FDA or DailyMed label, or the peer-reviewed paper of record, and listed as a numbered reference you can open. Press releases, marketing pages and AI summaries are never treated as evidence.
• Citations checked against the source. Before a page is published, each reference is looked up in PubMed, DailyMed, ClinicalTrials.gov or the journal itself to confirm the authors, year and the exact figure quoted. A citation that cannot be confirmed is not published.
• Evidence graded, not adjectived. Compounds are graded by the strength of their human evidence (FDA-approved, clinical-stage or preclinical-only), and that grade travels with every claim. The grading rules are in our methodology.
• Provider reviews come from the company. A review describes what the provider itself publishes: its prices, care model, medications and pharmacy, plus public records such as FDA warning letters, which are linked to the letter on fda.gov. A warning letter is disclosed on the review; it does not by itself rule a provider out.
• Dated. Articles and reviews show the month they were last updated, and that date changes only when the page is re-checked against its sources.
• Drafting tools. Where AI assistance helps organize or draft material, the result is treated as a draft. A person checks every claim against the primary source before it is published.

Medical review, stated plainly: Aminoscope does not have a licensed clinician on staff as a named medical reviewer. Pages are checked against primary sources, not reviewed by a doctor, and we do not attach credentials we cannot stand behind. The details are in our editorial policy.

Our writers publish under consistent pen names, a long-standing practice in science and health journalism, so the work is judged on its sourcing rather than on a personality. These are stated to be pen names, not claims about a named person's real-world identity or credentials. Bylines are stable: the same name always means the same writer and beat, and each writer has a public ORCID iD linked from their profile.

If you find a misread figure, an outdated citation, a changed price or a broken source link, email editorial@aminoscope.com with the page and the sentence in question, ideally with the primary source. We check every report against the source of record. A substantive correction is noted on the page and the page's updated date is revised. The process is set out in our corrections policy.